Senescent Leydig cells release mitochondrial DNA fragments that drive epigenetic silencing of CYP17A1 and shift steroidogenesis from the Δ5 to the Δ4 pathway

Hypothesis

Aged Leydig cells accumulate mitochondrial damage that releases circulating mitochondrial DNA (mtDNA) fragments into the testicular interstitium. These mtDNA acts as a danger‑associated molecular pattern (DAMP) that activates cytosolic cGAS‑STING signaling in neighboring Leydig cells, leading to IFN‑β production and downstream recruitment of DNA methyltransferases (DNMT3A/B) to the promoter of CYP17A1. Epigenetic silencing of CYP17A1 blocks the 17α‑hydroxylase/17,20‑lyase step unique to the Δ5 pathway, forcing flux through the less efficient Δ4 route and exacerbating the StAR‑mediated cholesterol transport deficit. Consequently, the Δ5:Δ4 ratio falls, testosterone output declines, and senescent phenotypes are reinforced via IFN‑driven SASP amplification.

Mechanistic Basis

• Mitochondrial dysfunction in senescent Leydig cells increases mtDNA nucleoid leakage, a process documented in other tissues under oxidative stress [4].
• cGAS senses cytosolic dsDNA, triggering STING‑dependent IRF3 activation and type‑I interferon production, which has been shown to modulate steroidogenic enzyme expression in adrenal cells (analogous pathway) – this links inflammaging [2] to steroidogenic control.
• IFN‑β signaling upregulates DNMT3A/B via STAT1, causing CpG methylation of the CYP17A1 promoter; methylation of this promoter reduces transcription without affecting mRNA stability, a mechanism observed in hepatocellular carcinoma and relevant to steroidogenic genes.
• Loss of CYP17A1 blocks conversion of pregnenolone and progesterone to 17‑hydroxy precursors, shunting pregnenolone toward the Δ4 pathway via progesterone, which is less efficient due to lower 3β‑HSD activity and higher product inhibition.
• The resulting drop in Δ5‑derived DHEA and androstenedione reduces negative feedback on GnRH/LH, yet chronic LH exposure in aged testes fails to rescue testosterone because the enzymatic block persists, creating a vicious loop.

Testable Predictions

1. Aged murine testes will show elevated interstitial mtDNA concentrations correlated with increased cGAS‑STING phosphorylation and IFN‑β levels in Leydig cells (immunofluorescence and ELISA).
2. Pharmacological inhibition of cGAS (e.g., with RU.521) or STING (C‑176) in aged mice will restore CYP17A1 promoter hypomethylation, increase Δ5 pathway metabolites (pregnenolone, DHEA), and raise the Δ5:Δ4 ratio toward youthful levels.
3. Leydig‑specific overexpression of DNMT3A will phenocopy the aged Δ5:Δ4 shift even in young mice, whereas DNMT3A knockdown in aged Leydig cells will rescue CYP17A1 expression and testosterone production despite persistent StAR deficiency.
4. Administration of a senolytic that clears mtDNA‑rich senescent Leydig cells (e.g., navitoclax) will reduce interstitial mtDNA, lower IFN‑β signaling, and improve both StAR expression and Δ5 pathway flux.

Experimental Design

• Model: C57BL/6 mice aged 24 months vs. 3‑month controls; Leydig‑specific Cre‑Rosa26‑tdTomato lineage tracing to isolate senescent (p16^High) cells.
• Readouts: LC‑MS/MS steroid profiling to quantify pregnenolone, DHEA, androstenedione, testosterone; bisulfite sequencing of CYP17A1 promoter; qPCR/Western for StAR, TSPO, 3β‑HSD, CYP17A1; ELISA for IFN‑β; mtDNA quantification by qPCR of mitochondrial ND1 gene in interstitial fluid.
• Interventions: (i) cGAS inhibitor RU.521 (10 mg/kg i.p. thrice weekly); (ii) Leydig‑specific AAV‑shDNMT3A; (iii) navitoclax senolytic regimen.
• Analysis: Two‑way ANOVA with post‑hoc Tukey; significance set at p<0.05. Falsifiability: If cGAS/STING inhibition fails to alter CYP17A1 methylation or Δ5:Δ4 ratio, the hypothesis is refuted.

Potential Impact

Linking mitochondrial DAMP signaling to epigenetic reprogramming provides a mechanistic bridge between inflammaging, mitochondrial decline, and the observed steroidogenic pathway shift. It suggests that targeting the cGAS‑STING‑DNMT axis could simultaneously improve StAR‑dependent cholesterol transport and restore Δ5 pathway efficiency, offering a dual‑action strategy for late‑onset hypogonadism that extends beyond senolytic clearance alone.